Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease.

Algamdi M, Sadatsafavi M, Fisher JH, Morisset J, Johannson KA, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Shapera S, To T, Wilcox PG, Guler S, Ryerson CJ.

Chest. 2019 Apr 30. pii: S0012-3692(19)30885-2. doi: 10.1016/j.chest.2019.04.016. [Epub ahead of print]

2.

Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease.

Fidler L, Doubelt I, Kandel S, Fisher JH, Mittoo S, Shapera S.

Lung. 2019 Jun;197(3):277-284. doi: 10.1007/s00408-019-00212-9. Epub 2019 Mar 5.

PMID:
30838434
3.

Biallelic loss of function variants in ATP1A2 cause hydrops fetalis, microcephaly, arthrogryposis and extensive cortical malformations.

Monteiro FP, Curry CJ, Hevner R, Elliott S, Fisher JH, Turocy J, Dobyns WB, Costa LA, Freitas E, Kitajima JP, Kok F.

Eur J Med Genet. 2019 Jan 25. pii: S1769-7212(18)30802-4. doi: 10.1016/j.ejmg.2019.01.014. [Epub ahead of print]

PMID:
30690204
4.

YouTube Videos as a Source of Misinformation on Idiopathic Pulmonary Fibrosis.

Goobie GC, Guler SA, Johannson KA, Fisher JH, Ryerson CJ.

Ann Am Thorac Soc. 2019 May;16(5):572-579. doi: 10.1513/AnnalsATS.201809-644OC.

PMID:
30608877
5.

Role of a Regional Multidisciplinary Conference in the Diagnosis of Interstitial Lung Disease.

Grewal JS, Morisset J, Fisher JH, Churg AM, Bilawich AM, Ellis J, English JC, Hague CJ, Khalil N, Leipsic J, Mayo J, Muller NL, Murphy D, Wright JL, Ryerson CJ.

Ann Am Thorac Soc. 2019 Apr;16(4):455-462. doi: 10.1513/AnnalsATS.201811-794OC.

PMID:
30608873
6.

Systematic review of content and quality of idiopathic pulmonary fibrosis review articles.

Milne KM, Chan C, Fisher JH, de Boer K, Ryerson CJ.

ERJ Open Res. 2018 Dec 21;4(4). pii: 00156-2018. doi: 10.1183/23120541.00156-2018. eCollection 2018 Oct.

7.

Procedure volume and mortality after surgical lung biopsy in interstitial lung disease.

Fisher JH, Shapera S, To T, Marras TK, Gershon A, Dell S.

Eur Respir J. 2019 Feb 21;53(2). pii: 1801164. doi: 10.1183/13993003.01164-2018. Print 2019 Feb.

PMID:
30487208
8.

A Prospective, Longitudinal Examination of the Influence of Childhood Home and School Contexts on Psychopathic Characteristics in Adolescence.

Fisher JH, Brown JL.

J Youth Adolesc. 2018 Oct;47(10):2041-2059. doi: 10.1007/s10964-018-0861-2. Epub 2018 May 28.

PMID:
29808318
9.

Using Goal Achievement Training in juvenile justice settings to improve substance use services for youth on community supervision.

Fisher JH, Becan JE, Harris PW, Nager A, Baird-Thomas C, Hogue A, Bartkowski JP, Wiley T; JJ-TRIALS Cooperative.

Health Justice. 2018 Apr 30;6(1):10. doi: 10.1186/s40352-018-0067-4.

10.

A model for rigorously applying the Exploration, Preparation, Implementation, Sustainment (EPIS) framework in the design and measurement of a large scale collaborative multi-site study.

Becan JE, Bartkowski JP, Knight DK, Wiley TRA, DiClemente R, Ducharme L, Welsh WN, Bowser D, McCollister K, Hiller M, Spaulding AC, Flynn PM, Swartzendruber A, Dickson MF, Fisher JH, Aarons GA.

Health Justice. 2018 Apr 13;6(1):9. doi: 10.1186/s40352-018-0068-3.

11.

Perceived Need for Treatment and Engagement in Mental Health Services Among Community-Referred Racial/Ethnic Minority Adolescents.

Fisher JH, Lichvar E, Hogue A, Dauber S.

Adm Policy Ment Health. 2018 Sep;45(5):751-764. doi: 10.1007/s10488-018-0863-0.

PMID:
29525929
12.

Medical Students' Acquisition of Adolescent Interview Skills after Coached Role Play.

Kaul P, Fisher JH, Hanson JL.

J Pediatr Adolesc Gynecol. 2018 Apr;31(2):102-106. doi: 10.1016/j.jpag.2017.11.003. Epub 2017 Nov 23.

PMID:
29175430
13.

The Benefits of Community and Juvenile Justice Involvement in Organizational Research.

Leukefeld CG, Cawood M, Wiley T, Robertson AA, Fisher JH, Arrigona N, Donohue P, Staples-Horne M, Harris PW, Dembo R, Roysden J, Marks KR; JJ-TRIALS Cooperative.

J Juv Justice. 2017;6(1):112-124.

14.

In Response.

Flexman AM, Roughead T, Fisher JH, Sewell D, Ryerson CJ.

Anesth Analg. 2017 May;124(5):1742-1743. doi: 10.1213/ANE.0000000000002035. No abstract available.

PMID:
28426590
15.

Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment.

Fisher JH, Al-Hejaili F, Kandel S, Hirji A, Shapera S, Mura M.

Respir Med. 2017 Apr;125:65-71. doi: 10.1016/j.rmed.2017.03.006. Epub 2017 Mar 6.

16.

Development of a model web-based system to support a statewide quality consortium in radiation oncology.

Moran JM, Feng M, Benedetti LA, Marsh R, Griffith KA, Matuszak MM, Hess M, McMullen M, Fisher JH, Nurushev T, Grubb M, Gardner S, Nielsen D, Jagsi R, Hayman JA, Pierce LJ; Michigan Radiation Oncology Quality Consortium.

Pract Radiat Oncol. 2017 May - Jun;7(3):e205-e213. doi: 10.1016/j.prro.2016.10.002. Epub 2016 Oct 20.

PMID:
28196607
17.

X-ray transport and radiation response assessment (XTRRA) experiments at the National Ignition Facility.

Fournier KB, Brown CG Jr, Yeoman MF, Fisher JH, Seiler SW, Hinshelwood D, Compton S, Holdener FR, Kemp GE, Newlander CD, Gilliam RP, Froula N, Lilly M, Davis JF, Lerch MA, Blue BE.

Rev Sci Instrum. 2016 Nov;87(11):11D421.

PMID:
27910608
18.

Internet-Based Resources Frequently Provide Inaccurate and Out-of-Date Recommendations on Preoperative Fasting: A Systematic Review.

Roughead T, Sewell D, Ryerson CJ, Fisher JH, Flexman AM.

Anesth Analg. 2016 Dec;123(6):1463-1468. Review.

PMID:
27644057
19.

The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry.

Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M.

Can Respir J. 2016;2016:3562923. doi: 10.1155/2016/3562923. Epub 2016 Apr 5.

20.

Accuracy and Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis.

Fisher JH, O'Connor D, Flexman AM, Shapera S, Ryerson CJ.

Am J Respir Crit Care Med. 2016 Jul 15;194(2):218-25. doi: 10.1164/rccm.201512-2393OC.

PMID:
26849779
21.

The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry.

Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M.

Can Respir J. 2015 Nov 2. pii: 17206. [Epub ahead of print] No abstract available.

PMID:
26523546
22.

Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.

Fisher JH, Johnson SR, Chau C, Kron AT, Granton JT.

Can Respir J. 2015 Jan-Feb;22(1):42-6. Epub 2014 Dec 18.

23.

Radiochromic film measurement of spatial uniformity for a laser generated x-ray environment.

Fisher JH, Newlander CD, Horton R, Fournier KB, Emig J, Patterson R, Davis JF, Seiler S, Jenkins PP.

Rev Sci Instrum. 2012 Oct;83(10):10E137. doi: 10.1063/1.4746811.

PMID:
23126958
24.

The x-ray source application test cassette for radiation exposures at the OMEGA laser.

Fournier KB, Rekow V, Emig J, Fisher JH, Newlander CD, Horton R, Davis J.

Rev Sci Instrum. 2012 Oct;83(10):10E136. doi: 10.1063/1.4734036.

PMID:
23126957
25.

Recording EEG in immature rats with a novel miniature telemetry system.

Zayachkivsky A, Lehmkuhle MJ, Fisher JH, Ekstrand JJ, Dudek FE.

J Neurophysiol. 2013 Feb;109(3):900-11. doi: 10.1152/jn.00593.2012. Epub 2012 Oct 31.

26.

A test cassette for x-ray-exposure experiments at the National Ignition Facility.

Fournier KB, Celeste J, Rekow V, Bopp DR, May MJ, Fisher JH, Horton R, Newlander CD, Jenkins P, Trautz K.

Rev Sci Instrum. 2010 Jul;81(7):075113. doi: 10.1063/1.3470684.

PMID:
20687765
27.

Sexual dimorphism of the zebra finch syrinx indicates adaptation for high fundamental frequencies in males.

Riede T, Fisher JH, Goller F.

PLoS One. 2010 Jun 29;5(6):e11368. doi: 10.1371/journal.pone.0011368.

28.

Surfactant protein D enhances Pneumocystis infection in immune-suppressed mice.

Vuk-Pavlovic Z, Mo EK, Icenhour CR, Standing JE, Fisher JH, Limper AH.

Am J Physiol Lung Cell Mol Physiol. 2006 Mar;290(3):L442-9. Epub 2005 Sep 30.

29.

Alveolar surfactant protein D content modulates bleomycin-induced lung injury.

Casey J, Kaplan J, Atochina-Vasserman EN, Gow AJ, Kadire H, Tomer Y, Fisher JH, Hawgood S, Savani RC, Beers MF.

Am J Respir Crit Care Med. 2005 Oct 1;172(7):869-77. Epub 2005 Jun 30.

30.

Serum levels of surfactant protein D are increased in mice with lung tumors.

Zhang F, Pao W, Umphress SM, Jakowlew SB, Meyer AM, Dwyer-Nield LD, Nielsen LD, Takeda K, Gelfand EW, Fisher JH, Zhang L, Malkinson AM, Mason RJ.

Cancer Res. 2003 Sep 15;63(18):5889-94.

31.

Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability.

Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, Kim KS, McCormack FX.

J Clin Invest. 2003 May;111(10):1589-602.

32.

Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex.

Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE.

J Immunol. 2002 Oct 1;169(7):3978-86.

34.
35.

Lymphocyte activation in the lungs of SP-D null mice.

Fisher JH, Larson J, Cool C, Dow SW.

Am J Respir Cell Mol Biol. 2002 Jul;27(1):24-33.

PMID:
12091242
36.

Impaired clearance of apoptotic cells from cystic fibrosis airways.

Vandivier RW, Fadok VA, Ogden CA, Hoffmann PR, Brain JD, Accurso FJ, Fisher JH, Greene KE, Henson PM.

Chest. 2002 Mar;121(3 Suppl):89S. No abstract available.

PMID:
11893715
37.

The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry.

Marra CA, Esdaile JM, Guh D, Fisher JH, Chalmers A, Anis AH.

Arthritis Rheum. 2001 Jun;45(3):240-5.

38.

Expression and localization of a novel Rab small G protein (Rab38) in the rat lung.

Osanai K, Iguchi M, Takahashi K, Nambu Y, Sakuma T, Toga H, Ohya N, Shimizu H, Fisher JH, Voelker DR.

Am J Pathol. 2001 May;158(5):1665-75.

39.

Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung.

LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, Burhans MS, Korfhagen TR.

J Immunol. 2000 Oct 1;165(7):3934-40.

40.

Standardization and decomposition of rates: useful analytic techniques for behavior and health studies.

Wang J, Rahman A, Siegal HA, Fisher JH.

Behav Res Methods Instrum Comput. 2000 May;32(2):357-66.

PMID:
10875185
41.

Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice.

Wert SE, Yoshida M, LeVine AM, Ikegami M, Jones T, Ross GF, Fisher JH, Korfhagen TR, Whitsett JA.

Proc Natl Acad Sci U S A. 2000 May 23;97(11):5972-7.

42.

Pulmonary-specific expression of SP-D corrects pulmonary lipid accumulation in SP-D gene-targeted mice.

Fisher JH, Sheftelyevich V, Ho YS, Fligiel S, McCormack FX, Korfhagen TR, Whitsett JA, Ikegami M.

Am J Physiol Lung Cell Mol Physiol. 2000 Feb;278(2):L365-73.

44.

Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo.

Korfhagen TR, Sheftelyevich V, Burhans MS, Bruno MD, Ross GF, Wert SE, Stahlman MT, Jobe AH, Ikegami M, Whitsett JA, Fisher JH.

J Biol Chem. 1998 Oct 23;273(43):28438-43.

45.

Surfactant proteins A and D increase in response to intratracheal lipopolysaccharide.

McIntosh JC, Swyers AH, Fisher JH, Wright JR.

Am J Respir Cell Mol Biol. 1996 Oct;15(4):509-19.

PMID:
8879185
46.

Enhancing substance abuse treatment with case management. Its impact on employment.

Siegal HA, Fisher JH, Rapp RC, Kelliher CW, Wagner JH, O'Brien WF, Cole PA.

J Subst Abuse Treat. 1996 Mar-Apr;13(2):93-8.

PMID:
8880666
47.

Presenting problems of substance abusers in treatment: implications for service delivery and attrition.

Siegal HA, Fisher JH, Rapp RC, Wagner JH, Forney MA, Callejo V.

Am J Drug Alcohol Abuse. 1995 Feb;21(1):17-26.

PMID:
7762541
48.

Expression of pulmonary surfactant protein D in rat gastric mucosa.

Fisher JH, Mason R.

Am J Respir Cell Mol Biol. 1995 Jan;12(1):13-8.

PMID:
7811466
49.

The strengths perspective of case management: a promising inpatient substance abuse treatment enhancement.

Siegal HA, Rapp RC, Kelliher CW, Fisher JH, Wagner JH, Cole PA.

J Psychoactive Drugs. 1995 Jan-Mar;27(1):67-72.

PMID:
7602442
50.

Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.

Zamora MR, Fullerton DA, Campbell DN, Leone S, Diercks MJ, Fisher JH, Badesch DB, Grover FL.

Transplant Proc. 1994 Oct;26(5 Suppl 1):49-51.

PMID:
7940974

Supplemental Content

Loading ...
Support Center